Although the GABAergic benzodiazepines (BZDs) and Z-drugs (zolpidem, zopiclone, and
zaleplon) are FDA-approved for insomnia disorders with a strong evidence base, they have …

Purpose Insomnia is problematic for older adults. After behavioral modifications fail to show
adequate response, pharmacologic options are used. The pharmacokinetics of agents used …

Sleep disorders are common in the general population and even more so in clinical practice,
yet are relatively poorly understood by doctors and other health care practitioners. These …

Major depression is a debilitating and recurrent disorder with a substantial lifetime risk and a
high social cost. Depressed patients generally display co-morbid symptoms, and depression …

This British Association for Psychopharmacology guideline replaces the original version
published in 2010, and contains updated information and recommendations. A consensus …

OBJECTIVE: While trazodone is approved for the treatment of depression, the off-label use
of this medication for insomnia has surpassed its usage as an antidepressant. In this …

Trazodone is a triazolopyridine derivative that belongs to the class of serotonin receptor
antagonists and reuptake inhibitors (SARIs). The drug is approved and marketed in several …

Background Insomnia disorder is a subjective condition of unsatisfactory sleep (eg sleep
onset, maintenance, early waking, impairment of daytime functioning). Insomnia disorder …

Objective: Trazodone, a triazolopyridine antidepressant, is currently the second most
commonly prescribed agent for the treatment of insomnia due to its sedating qualities. Given …

Insomnia and daytime sleepiness are often associated with depression. The possible
relationships between sleep difficulties and depression are numerous. Insomnia and other …